Article Details

JHL Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin ...

Retrieved on: 2018-07-05 05:00:00

Tags for this article:

Click the tags to see associated articles and topics

JHL Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin .... View article details on hiswai:

Excerpt

<div>JHL Biotech is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, <b>Sequoia Capital</b>, Biomark Capital, Milestone Capital, ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up